Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

VISTA, an AI-controlled data loop system, guides large-scale antibody design from scratch for applications in cancer therapy.

Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, discusses the importance ...

For decades, the narrative around Parkinson’s disease treatment has focused primarily on dopamine replacement. The loss of dopaminergic neurons in the substantia nigra is well recognized and drives ...

Ignoring the vibration feature entirely, these balls get the job done as standard massage balls. The size works well for foot ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the publication of a ...

The FDA cited trial design concerns and lack of substantial evidence in denying approval for Replimune’s biologics license application in advanced melanoma.

The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (CT03767348) trial in advanced melanoma was not ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.